Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ippei Shimomura"'
Autor:
Masayoshi Onitsuka, Mitsuo Umetsu, Takeshi Omasa, Izumi Kumagai, Shota Konno, Takeshi Nakanishi, Ryutaro Asano, Mai Okada, Katsuhiro Hosokawa, Ippei Shimomura, Hiromi Ogata, Shintaro Taki, Kyoko Arai
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
Designing non-natural antibody formats is a practical method for developing highly functional next-generation antibody drugs, particularly for improving the therapeutic efficacy of cancer treatments. One approach is constructing bispecific antibodies
Autor:
Masayoshi Onitsuka, Shota Konno, Mitsuo Umetsu, Yu Katayose, Toshio Kudo, Izumi Kumagai, Akiko Ito, Mai Okada, Hiroki Hayashi, Yosuke Masakari, Ryutaro Asano, Ippei Shimomura, Shozo Furumoto, Kyoko Arai, Ryota Orimo, Michiaki Unno, Shintaro Taki, Takeshi Omasa, Hiromi Ogata
Publikováno v:
mAbs
One approach to creating more beneficial therapeutic antibodies is to develop bispecific antibodies (bsAbs), particularly IgG-like formats with tetravalency, which may provide several advantages such as multivalent binding to each target antigen. Alt
Autor:
Izumi Kumagai, Ippei Shimomura, Ryutaro Asano, Takeshi Nakanishi, Shintaro Taki, Mitsuo Umetsu, Keiko Ikoma
Publikováno v:
Journal of Biological Chemistry. 286:1812-1818
Diabodies (Dbs) and tandem single-chain variable fragments (taFv) are the most widely used recombinant formats for constructing small bispecific antibodies. However, only a few studies have compared these formats, and none have discussed their bindin
Autor:
Toshio Kudo, Ippei Shimomura, Yu Katayose, Kyoko Arai, Izumi Kumagai, Takeshi Nakanishi, Yasuhiro Watanabe, Mitsuo Umetsu, Hiroko Kawaguchi, Hiroki Hayashi, Hideo Ohtsuka, Shinichi Egawa, Hiroshi Yoshida, Tadao Ishida, Michiaki Unno, Ryutaro Asano, Hiromi Ogata, Kohzoh Imai, Hiroshi Yasui
Publikováno v:
Oncology reports. 26(4)
We performed in vitro and in vivo experiments of the anti-epidermal growth factor receptor (EGFR) x anti-CD3 bispecific diabody (hEx3-Db) with the IgG-like bispecific antibodies (BsAbs) (hEx3-scFv-Fc and hEx3-scDb-Fc) and the anti-EGFR therapeutic an
Autor:
Ryutaro Asano, Takashi Kumagai, Keisuke Nagai, Shintaro Taki, Ippei Shimomura, Kyoko Arai, Hiromi Ogata, Mai Okada, Fumitaka Hayasaka, Hideaki Sanada, Takeshi Nakanishi, Teemu Karvonen, Hiroki Hayashi, Yu Katayose, Michiaki Unno, Toshio Kudo, Mitsuo Umetsu, Izumi Kumagai
Publikováno v:
PEDS: Protein Engineering, Design & Selection; May2013, Vol. 26 Issue 5, p359-367, 9p